ArticleScientific reports2025
Gross hematuria after COVID-19 mRNA vaccination and kidney function trajectory in IgA nephropathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gross hematuria (GH) following COVID-19 mRNA vaccination has been increasingly reported in patients with IgA nephropathy (IgAN). This study assessed the effect of post-vaccination GH on kidney function. A total of 441 Japanese outpatients with biopsy-confirmed IgAN (median age: 51 years; 56% female; baseline eGFR: 57 mL/min/1.73 m²) were classified into three groups: unvaccinated (n = 25), vaccinated without GH (n = 391), and vaccinated with GH (n = 25). Kidney function was evaluated at approximately 1 year (midpoint) and 2 years (endpoint) after baseline. The annual eGFR change (ΔeGFR: mL/min/1.73 m²/year) at midpoint was - 1.16, - 1.03, and - 2.50, respectively. The GH group showed a significantly greater decline compared to the non-GH group (p = 0.015), and GH was significantly associated with greater eGFR decline at midpoint (odds ratio: 2.97, p = 0.038). At the endpoint, the ΔeGFR was - 0.45, - 1.93, and - 1.72, with no significant differences among the groups (p = 0.773). In this cohort, GH after vaccination was observed to be associated with a greater short-term decline in kidney function, although the retrospective design precludes establishing causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.